CrossRef The association of multiple metabolic disorders with the severity of fasting blood glucose and hepatic steatosis in a Chinese population with MAFLD: a cross-sectional study of over 3000 participants Xue Qu, Shanshan Jin, Yuqing Shi, Weisong Zhang, Delong Cong, Yangyang Liu Scientific Reports .2025;[Epub] CrossRef Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz Current Medical Research and Opinion .2025
Semaglutide is a GLP-1 receptor agonist , which means it works with hormone pathways involved in appetite, fullness, digestion, and blood sugar response
Generally, your prescribing doctor will advise you on whether or not it's a good idea, but the chances of significant, serious negative side effects are slim
Intraepithelial lymphocytes (IELs), a distinct lineage of T cells residing within the epithelial layer, express high levels of GLP-1 receptors
Tirzepatide's dual GLP-1/GIP action outperformed GLP-1-only drugs like semaglutide, suggesting GIP adds real value beyond just GLP-1